Analysts Set Forward Pharma A/S (FWP) Target Price at $18.67
Shares of Forward Pharma A/S (NASDAQ:FWP) have earned an average recommendation of “Buy” from the six analysts that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $18.67.
A number of analysts recently weighed in on FWP shares. BidaskClub raised shares of Forward Pharma A/S from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 30th. ValuEngine raised shares of Forward Pharma A/S from a “sell” rating to a “hold” rating in a research note on Saturday, June 17th. Finally, Jefferies Group LLC restated a “hold” rating and set a $6.00 target price (up previously from $5.00) on shares of Forward Pharma A/S in a research report on Wednesday, September 27th.
A number of institutional investors have recently added to or reduced their stakes in the business. Senzar Asset Management LLC grew its stake in Forward Pharma A/S by 38.2% in the 2nd quarter. Senzar Asset Management LLC now owns 652,500 shares of the biotechnology company’s stock worth $13,265,000 after acquiring an additional 180,200 shares in the last quarter. Baupost Group LLC MA increased its position in shares of Forward Pharma A/S by 3.9% during the first quarter. Baupost Group LLC MA now owns 5,575,407 shares of the biotechnology company’s stock worth $119,927,000 after acquiring an additional 208,107 shares during the period. Eqis Capital Management Inc. increased its position in shares of Forward Pharma A/S by 25.5% during the second quarter. Eqis Capital Management Inc. now owns 20,178 shares of the biotechnology company’s stock worth $410,000 after acquiring an additional 4,097 shares during the period. Alps Advisors Inc. purchased a new position in shares of Forward Pharma A/S during the second quarter worth approximately $866,000. Finally, BlueMountain Capital Management LLC increased its position in shares of Forward Pharma A/S by 15.3% during the second quarter. BlueMountain Capital Management LLC now owns 1,511,043 shares of the biotechnology company’s stock worth $26,982,000 after acquiring an additional 200,000 shares during the period. 21.85% of the stock is owned by institutional investors.
Forward Pharma A/S (NASDAQ:FWP) traded up 2.65% during midday trading on Friday, reaching $6.19. The company’s stock had a trading volume of 42,895 shares. Forward Pharma A/S has a 12-month low of $5.20 and a 12-month high of $33.00.
The firm also recently announced an annual dividend, which was paid on Monday, September 11th. Shareholders of record on Thursday, September 7th were paid a $22.903 dividend. The ex-dividend date of this dividend was Wednesday, September 6th. Forward Pharma A/S’s payout ratio is -3,249.25%.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/analysts-set-forward-pharma-as-fwp-target-price-at-18-67/1605971.html.
About Forward Pharma A/S
Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.
Receive News & Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.